Because most cancer cells have increased resistance to the activation of MOMP and escape apoptosis as a result of various modifications in apoptosis regulators, including Bcl-2 family members, p53, and caspases [34], various mitochondrion-targeted cancer treatment strategies have been developed in the last decade [35,36]. This evidence concerns the gene BCL2 and cancer.